



Scientific Letter

Factors Associated With Large Airway Collapse in Severe Asthma



To the Director,

Large airway collapse (LAC) is mainly caused by tracheobronchomalacia (TBM) and excessive dynamic airway collapse (EDAC).¹ It is defined by a decrease of at least 50% in the cross-sectional area of the tracheobronchial lumen.^{1,2} TBM is characterised by a weakness of the tracheobronchial cartilaginous wall, while EDAC is defined by the presence of excessive bulging of the posterior membrane into the airway lumen,^{3–5} without anomalies in the cartilaginous structures.³ LAC is an underdiagnosed condition, especially EDAC, with nonspecific symptoms that can mimic other respiratory diseases, such as asthma. Symptoms are shortness of breath, cough, stridor, respiratory infections and difficulty in expectorating.

Severe asthma accounts for 5% of patients with asthma.⁶ While TBM is a condition related with severe asthma, the association between asthma and EDAC has not been described.^{7,8} Our objective was to study the prevalence of LAC and EDAC in patients with severe asthma, and to analyse the associated factors.

This was an observational prospective multicentric study conducted in the Respiratory Departments of Hospital Sant Pau (Barcelona) and Hospital Germans Trias i Pujol (Badalona) between years 2017 and 2019. Twenty patients with severe asthma consecutively selected in Asthma Units, over 18 years old without exacerbations for at least the previous four weeks were included. Patients with other respiratory conditions, with mild-to-moderate asthma, previously diagnosed tracheal conditions or with previous tracheostomy were excluded.

Demographic, anthropometric and clinical data were collected. Clinical data included questionnaires about symptoms (Asthma Control Test) and quality of life (Sydney Asthma Quality of Life Questionnaire), asthma treatment, exacerbations during the previous year, pulmonary function and laboratory determinations. A flexible bronchoscopy (FBC) was performed under mild sedation, using a bronchoalveolar lavage (BAL) in medium lobe or lingula bronchi for microbiological cultures and cell count. Bronchoscopy images were videorecorded in order to calculate the degree of the collapse. LAC was diagnosed when a difference of at least 50% in the cross-sectional area of the lumen between inspiration and expiration at tidal volume was seen in one or more of the following locations: trachea, right main bronchus or left main bronchus. Study protocol was approved by Ethics Committee at our institution (PI-16-174), and all subjects gave their informed consent. Quantitative variables were described using median (interquartile range), and qualitative variables were described using absolute and relative

frequencies. Comparisons were conducted using Mann–Whitney *U* in the case of quantitative variables, and Fisher's exact test for qualitative variables. Those variables with *p* < 0.05 were included in a univariate analysis using logistic regression. Calculations were performed using SPSS v22 (Chicago, IL, USA).

Seven of our 20 severe asthmatic patients (35%) had LAC, 6 of them (30%) EDAC and one patient TBM (5%). Main bronchi was the most frequent location (5/7). Patients with LAC were older (70 years vs 49 years, *p* = 0.046) and had lower pulmonary function (FEV1%; 51 vs 66, *p* = 0.03), with neutrophilia in bronchoalveolar fluid (30.5% vs 3%, *p* = 0.03) and were more likely to be colonised by potentially pathogen microorganisms (PPM) (66.7% vs 8.3%, *p* = 0.009) especially *Haemophilus* spp. (50% vs 8.3%, *p* = 0.04). These patients had more symptoms and had a higher body mass index (BMI), without statistical significance. No differences in other variables were found (**Tables 1 and 2**). In the univariate logistic analysis, only colonisation with PPM was associated with an increased risk for LAC (OR 22 (1.54–314); *p* = 0.023).

In our study, prevalence of LAC was 35% in patients with severe asthma, mainly EDAC. These patients were older, with worse pulmonary function, more respiratory symptoms, more neutrophil count in bronchoalveolar fluid, and with higher prevalence of colonisation by PPM.

Prevalence of LAC is lower than in the only previous study performed exclusively in asthmatic patients. Dal Negro and cols evaluated 202 asthmatic patients and found an increase in the prevalence related to asthma severity. Prevalence of EDAC and TBM measured endoscopically was 69.2% and 18.4%, respectively.⁹ This difference in prevalence between the two studies could be related to the differences in gender, mean pulmonary function differences (68.5% females and FEV1% 48.5 in Dal Negro' study) and the smaller sample size of our study. Recently, Cosío et al., in 100 uncontrolled severe asthmatics found lower prevalence of LAC than ours; 3%.¹⁰ However, the studies are not comparable as the objectives were clearly different. Other studies focusing on COPD patients have described prevalence of LAC between 9 and 70%.¹ The use of different techniques to define LAC (FBC, CT scan or magnetic resonance) could be the reason of such variability, as well as the difference in the degree of collapse used to define LAC, or the respiratory manoeuvre required to the patient. We believe that the FBC is the best method to evaluate LAC in severe asthma, since it adds information on the characteristics of the airway, cellularity, inflammation or microbiological data.

Our patients with LAC had a higher BMI. The increase on collapsibility in obese patients could be explained by increased intrathoracic pressure that facilitates collapse of the airways at the end of expiration, especially when airway walls are damaged.¹¹

Table 1

Demographic, Anthropometric and Clinical Characteristics.

	LAC (7)	No LAC (13)	p value
Age (years), med (IQR)	70 (58–74)	49 (37.5–69)	0.046
BMI, med (IQR)	30.3 (27–31)	27.1 (23–31)	0.183
Obesity (%)	57	23	0.128
Smoking (%)	28.6	15.4	0.482
Prick test+ (%)	57	77	0.357
IgE kU/l, med (IQR)	129 (62–747)	185 (59–463)	1
Budesonide mcg, med (IQR)	1600 (800–1600)	1600 (1140–1600)	0.817
Use of oral maintenance corticosteroids (%)	14	23	0.639
Exacerbations, med (IQR)	4 (2–4)	3 (1.5–4)	0.536
ACT med (IQR)	15 (13–18)	17 (12–23)	0.393
FEV1%, med (IQR)	51 (46–70)	66 (58–93)	0.030
Age of onset, med (IQR)	40 (6–50)	27 (2.5–51)	0.438
Years since asthma diagnostic med (IQR)	24 (20–52)	16 (8–39)	0.536
AQLQ, med (IQR)	4.2 (1.2–6.9)	4 (1.7–6.63)	1
Women (%)	71	69	0.919

LAC: large airway collapse; BMI: body mass index; ACT: Asthma Control Test; AQLQ: Asthma Quality of Life Questionnaire; med: median; IQR: interquartile range.

Table 2

Microbiological and Inflammatory Characteristics.

	LAC (7)	No LAC (13)	p
Col Pseudomona (%)	0	8.3	0.467
Col <i>Staphylococcus aureus</i> (%)	16.7	0	0.146
Col Pneumococ (%)	16.7	0	0.146
Col <i>Haemophilus</i> (%)	50	8.3	0.045
Col PPM (%)	66.7	8.3	0.009
BAL neutrophils % med (IQR)	30.5 (8.5–49.5)	3 (2–4.5)	0.036
BAL eosinophils % med (IQR)	0.5 (0–14)	0 (0–2)	0.733
Eosinophils serum cel/mm ³ , med (IQR)	100 (100–300)	200 (100–400)	0.351
Eosinophils serum % med (IQR)	2.2 (1.7–4.6)	3.6 (1.1–5.2)	0.536

LAC: large airways collapse; med: median; IQR: interquartile range; PPM: potentially pathogenic microorganisms.

Boiselle et al. described that COPD patients with BMI over 35 had a mean tracheal collapse of 69%, while in those with BMI below 35 mean tracheal collapse was only 5%.¹²

In our study patients with LAC had poorer pulmonary function, which is not in line with previous studies in patients with COPD,^{13–15} where no relation was found between LAC and FEV1.¹⁵ On the other hand, Fischer et al.,¹⁶ described that FEV1 was 18% lower in children with cystic fibrosis when TBM was present. In the same study, the authors found an increase in the prevalence of infection by *Pseudomonas aeruginosa* in patients with TBM.¹⁶ In our study we observed an increase in the colonisation by PPM, especially *Haemophilus influenza*; to our knowledge is the first paper that it has been described in patients with LAC and severe asthma.

The damage to the bronchial wall associated with LAC in asthmatic patients remains unclear but could be explained by different mechanisms, such as asthmatics are more prone to infections,¹⁷ their high levels of elastase derived from neutrophilic inflammation,¹⁸ the use of high dose of inhaled corticosteroids¹⁹ or the high intrathoracic pressure due to chronic cough.^{15,20} On the other hand, an increase in PPM colonisation and infection¹⁶ could be the result of the impaired drainage of mucus due to bronchial collapse. Our data showing bacterial colonisation and neutrophilia in these patients would support part of mechanisms discussed.

The article suffers from some limitations such as the sample size or not collecting follow-up data, which we believe are counteracted by the originality of the findings.

LAC, especially EDAC, is highly prevalent in patients with severe asthma, and it is associated with increased symptoms, worse pulmonary function and a higher risk of colonisation by PPM. Thus, it is a comorbidity which should be considered in patients with poor clinical control. Increased colonisation by PPM has not been previously described in patients with LAC and asthma. Whether this colonisation is a risk factor for LAC, or its consequence, is still to be elucidated. Studies with larger samples and a follow-up must be carried out.

Funding

Funded by a grant from Fundació Catalana de Pneumologia (FUCAP), 2018.

Conflict of Interests

The authors state that they have no conflict of interests.

References

- Mitropoulos A, Song WJ, Almaghouth F, Kemp S, Polkey M, Hull JH. Detection and diagnosis of large airway collapse: a systematic review. *ERJ Open Res*. 2021;7:00055–2021, <http://dx.doi.org/10.1183/23120541.00055-2021>.
- Murgu SD, Colt HG. Tracheobronchomalacia and excessive dynamic airway collapse. *Respirology*. 2006;11:388–406, <http://dx.doi.org/10.1111/j.1440-1843.2006.00862.x> [PMID: 16771908].
- Park JG, Edell ES. Dynamic airway collapse: distinct from tracheomalacia. *J Bronchol Intervent Pulmonol*. 2005;12:143–6. Available from: https://journals.lww.com/bronchology/Fulltext/2005/07000/Dynamic_Airway_Collapse_Distinct_From_5.aspx
- Wittenborg MH, Gyepes MT, Crocker D. Tracheal dynamics in infants with respiratory distress, stridor, and collapsing trachea. *Radiology*. 1967;88:653–62, <http://dx.doi.org/10.1148/88.4.653> [PMID: 6020927].
- Feist JH, Johnson TH, Wilson RJ. Acquired tracheomalacia: etiology and differential diagnosis. *Chest*. 1975;68:340–5, <http://dx.doi.org/10.1378/chest.68.3.340> [PMID: 169105].
- Quirce S, Plaza V, Picado C, Vennera M, Casafont J. Prevalence of uncontrolled severe persistent asthma in pneumology and allergy hospital units in Spain. *J Investig Allergol Clin Immunol*. 2011;21:466–71.
- Global Initiative for Asthma Scientific Committee. Global strategy for asthma management and prevention. 2022. Available from: <https://ginasthma.org>
- GEMA 5.2. Guía Española para el Manejo del Asma. Available from: www.gemasma.com.
- Dal Negro RW, Tognella S, Guerriero M, Richeletto C. Prevalence of tracheobronchomalacia and excessive dynamic airway collapse in bronchial asthma of different severity. *Multidiscip Respir Med*. 2013;8:32.
- Cosío BG, Shafiek H, Mosteiro M, Iglesias A, Gómez C, Toledo-Pons N, et al. Redefining the role of bronchoscopy in the workup of severe uncontrolled asthma in the era of biologics: a prospective study. *Chest*. 2023,

- <http://dx.doi.org/10.1016/j.chest.2023.03.012> [Epub ahead of print; S0012-3692(23)00354-9].
11. Behazin N, Jones SB, Cohen RI, Loring SH. Respiratory restriction and elevated pleural and esophageal pressures in morbid obesity. *J Appl Physiol*. 2010;108:212–8.
 12. Boiselle PM, Litmanovich DE, Michaud G, Roberts DH, Loring SH, Womble HM, et al. Dynamic expiratory tracheal collapse in morbidly obese COPD patients. *COPD*. 2013;10:604–10.
 13. Boiselle PM, Michaud G, Roberts DH, Loring SH, Womble HM, Millett ME, et al. Dynamic expiratory tracheal collapse in COPD. *Chest*. 2012;142:1539–44.
 14. Represas-Represas C, Leiro-Fernández V, Mallo-Alonso R, Botana-Rial MI, Tilve-Gómez A, Fernández-Vilar A. Excessive dynamic airway collapse in a small cohort of chronic obstructive pulmonary disease patients. *Ann Thorac Med*. 2015;10:118–22.
 15. Loring STH, O'Donnell CR, Feller-Kopman DJ, Ernst A. Central airway mechanics and flow limitation in acquired tracheobronchomalacia. *Chest*. 2007;131:1118–24.
 16. Fischer AJ, Singh SB, Adam RJ, Stoltz DA, Baranano ChF, Kao S, et al. Tracheomalacia is associated with lower FEV1 and *Pseudomonas* acquisition in children with CF. *Pediatr Pulmonol*. 2014;49:960–70.
 17. McDermott S, Barry SC, Judge EE, Collins S, de Jong PA, Tiddens HA, et al. Tracheomalacia in adults with cystic fibrosis: determination of prevalence and severity with dynamic cineCT. *Radiology*. 2009;252:577–88.
 18. Davis SD, Ferkol T. Identifying the origins of cystic fibrosis lung disease. *N Engl J Med*. 2013;368:2026–8.
 19. Shah V, Husta B, Mehta A, Ashok S, Ishikawa O, Stoffels G, et al. Association between inhaled corticosteroids and tracheobronchomalacia. *Chest*. 2020;157:1426–34.
 20. Feist JH, Johnson TH, Wilson RJ. Acquired tracheomalacia: etiology and differential diagnosis. *Chest*. 1975;68:340–5.
- Carlos Martinez Rivera ^{a,b,c,*}, Pere Serra Mitjà ^{a,b,c}, Felipe Andreo García ^{a,b,c}, Astrid Crespo-Lessmann ^{c,d}, Alan Jhunior Solis Solis ^{a,b,c}, Alfons Torrego ^{c,d}, Ignasi Garcia-Olive ^{a,b,c}, David Ramos-Barbón ^{c,d}, Toni Zapata Comas ^{a,b,c}, Vicente Plaza ^{c,d}, Jorge Abad ^{a,b,c}, Antoni Rosell ^{a,b,c}
- ^a Servicio de Neumología, Hospital Germans Trias i Pujol, Institut d'Investigació Germans Trias i Pujol, Badalona, Barcelona, Spain
^b Universitat Autònoma de Barcelona, Spain
^c Barcelona Respiratory Network (BRN), Spain
^d Servicio de Neumología y Alergia, Hospital de la Santa Creu i Sant Pau, Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau), Universidad Autónoma de Barcelona, Spain

Corresponding author.

E-mail address: carlosmartinezrivera.cmr@gmail.com
(C. Martinez Rivera).